lanosten-3-ol-32-al and Arteriosclerosis

lanosten-3-ol-32-al has been researched along with Arteriosclerosis* in 1 studies

*Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries [MeSH]

Reviews

1 review(s) available for lanosten-3-ol-32-al and Arteriosclerosis

Article	Year
Oxylanosterols as modifiers of cholesterol biosynthesis. Progress in lipid research, 1995, Volume: 34, Issue:2 In this review, the thinking and strategy that lead to the design of mechanism-based inhibitors of cholesterol biosynthesis have been recounted. This work began with a purely biochemical perspective on the mechanism of lanosterol demethylation. The final efforts focused on pharmacology and drug design thus bringing the basic science effort to a practical application. Most recently, a series of 15-oxalanosterols, which act as pure suppressors of HMG-CoA reductase lacking lanosterol demethylase inhibition properties has been identified. These molecules also lower serum cholesterol and show promise as potential agents for clinical evaluation. The utility of these compounds and validation of our hypothesis will have to await further testing. Topics: Arteriosclerosis; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lanosterol	1995

Article

Year

Oxylanosterols as modifiers of cholesterol biosynthesis.

Progress in lipid research, 1995, Volume: 34, Issue:2

In this review, the thinking and strategy that lead to the design of mechanism-based inhibitors of cholesterol biosynthesis have been recounted. This work began with a purely biochemical perspective on the mechanism of lanosterol demethylation. The final efforts focused on pharmacology and drug design thus bringing the basic science effort to a practical application. Most recently, a series of 15-oxalanosterols, which act as pure suppressors of HMG-CoA reductase lacking lanosterol demethylase inhibition properties has been identified. These molecules also lower serum cholesterol and show promise as potential agents for clinical evaluation. The utility of these compounds and validation of our hypothesis will have to await further testing.

Topics: Arteriosclerosis; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lanosterol

1995